News >

Novel Compound GPX-150 Shows Promise in Soft Tissue Sarcoma

Danielle Bucco
Published: Wednesday, Feb 22, 2017

Brian Van Tine, MD, PhD

Brian Van Tine, MD, PhD

The investigational compound 5-imino-13-deoxydoxorubicin (GPX-150) was active and well tolerated in patients with metastatic and nonresectable soft tissue sarcoma (STS), according to data from a single-arm phase II study presented at the 2016 Connective Tissue Oncology Society Annual Meeting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication